Given the presence of soluble urokinase plasminogen activator receptor (suPAR) in the serum and cerebrospinal fluid (CSF) of patients with neurological diseases (17–19), and the demonstrated role of suPAR in AKI and inflammation (20), we measured plasma suPAR levels and found them significantly elevated in the Mdm2-cKO group (Figure 2M). The gene discussed is MDM2; the disease is acute kidney injury.